CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer - Resultados de la búsqueda

visitante :: identificación

Depósito Digital de Documentos de la UAB

Página principal > Resultados de la búsqueda: CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

Buscar colecciones:

Ordenar por:	Mostrar resultados:	Formato de visualización:

La combinación booleana no ha dado resultados. Por favor combine los términos de búsqueda de otra manera.

1 CA19-9

19 decrease

1898 at

506 8

21 weeks

2971 as

53990 a

49 predictor

41587 of

28 overall

208 survival

33780 in

53990 a

308 randomized

394 phase

1233 III

455 trial

1 (MPACT)

41587 of

19 weekly

3 nab

7 paclitaxel

124 plus

5 gemcitabine

370 versus

5 gemcitabine

51 alone

33780 in

1977 patients

6733 with

99 metastatic

57 pancreatic

1534 cancer

Depósito Digital de Documentos de la UAB :: :: :: ::
Powered by v1.1.6
Mantenido por ::

Colaboramos

1		CA19-9
19		decrease
1898		at
506		8
21		weeks
2971		as
53990		a
49		predictor
41587		of
28		overall
208		survival
33780		in
53990		a
308		randomized
394		phase
1233		III
455		trial
1		(MPACT)
41587		of
19		weekly
3		nab
7		paclitaxel
124		plus
5		gemcitabine
370		versus
5		gemcitabine
51		alone
33780		in
1977		patients
6733		with
99		metastatic
57		pancreatic
1534		cancer